Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma.

French S, DuBois SG, Horn B, Granger M, Hawkins R, Pass A, Plummer E, Matthay K.

Pediatr Blood Cancer. 2013 May;60(5):879-84. doi: 10.1002/pbc.24351. Epub 2012 Sep 28.

PMID:
23024113
2.

[Radio iodized metaiodobenzylguanidine (MIBG) in the treatment of neuroblastoma: modalities and indications].

Défachelles AS, Cougnenc O, Carpentier P.

Bull Cancer. 2011 May;98(5):559-69. doi: 10.1684/bdc.2011.1353. Review. French.

3.

Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.

Mangel J, Buckstein R, Imrie K, Spaner D, Crump M, Tompkins K, Reis M, Perez-Ordonez B, Deodhare S, Romans R, Pennell N, Robinson JB, Hewitt K, Richardson P, Lima A, Pavlin P, Berinstein NL.

Semin Oncol. 2002 Feb;29(1 Suppl 2):56-69. Review.

PMID:
11842390
4.

131I-Metaiodobenzylguanidine therapy in children with advanced neuroblastoma.

DuBois SG, Matthay KK.

Q J Nucl Med Mol Imaging. 2013 Mar;57(1):53-65. Review.

PMID:
23474635
5.

Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma.

DuBois SG, Matthay KK.

Nucl Med Biol. 2008 Aug;35 Suppl 1:S35-48. doi: 10.1016/j.nucmedbio.2008.05.002. Review.

6.

Iodine-131 metaiodobenzylguanidine therapy for neuroblastoma: reports so far and future perspective.

Kayano D, Kinuya S.

ScientificWorldJournal. 2015;2015:189135. doi: 10.1155/2015/189135. Epub 2015 Mar 22. Review.

7.

The role of 131I-MIBG in high-risk neuroblastoma treatment.

Lessig MK.

J Pediatr Oncol Nurs. 2009 Jul-Aug;26(4):208-16. doi: 10.1177/1043454209340316. Review.

PMID:
19726792
8.

Contemporary approach to diagnosis and treatment of neuroblastoma.

Charron M.

Q J Nucl Med Mol Imaging. 2013 Mar;57(1):40-52. Review.

PMID:
23474634
9.

Promising therapeutic targets in neuroblastoma.

Matthay KK, George RE, Yu AL.

Clin Cancer Res. 2012 May 15;18(10):2740-53. doi: 10.1158/1078-0432.CCR-11-1939. Review.

10.

Optimization of molecular radiotherapy with [131I]-meta Iodobenzylguanidine for high-risk neuroblastoma.

Gaze MN, Gains JE, Walker C, Bomanji JB.

Q J Nucl Med Mol Imaging. 2013 Mar;57(1):66-78. Review.

PMID:
23474636
11.

A systematic review of 131I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma.

Wilson JS, Gains JE, Moroz V, Wheatley K, Gaze MN.

Eur J Cancer. 2014 Mar;50(4):801-15. doi: 10.1016/j.ejca.2013.11.016. Epub 2013 Dec 12. Review.

PMID:
24333097
12.

¹³¹I-Metaiodobenzylguanidine Theranostics in Neuroblastoma: Historical Perspectives; Practical Applications.

Parisi MT, Eslamy H, Park JR, Shulkin BL, Yanik GA.

Semin Nucl Med. 2016 May;46(3):184-202. doi: 10.1053/j.semnuclmed.2016.02.002. Review.

PMID:
27067500
13.

Children's Oncology Group's 2013 blueprint for research: neuroblastoma.

Park JR, Bagatell R, London WB, Maris JM, Cohn SL, Mattay KK, Hogarty M; COG Neuroblastoma Committee..

Pediatr Blood Cancer. 2013 Jun;60(6):985-93. doi: 10.1002/pbc.24433. Epub 2012 Dec 19. Review. Erratum in: Pediatr Blood Cancer. 2014 May;61(5):958. Mattay, Katherine M [corrected to Mattay, Katherine K].

PMID:
23255319
14.

Therapeutic nuclear medicine in pediatric malignancy.

Schmidt M, Baum RP, Simon T, Howman-Giles R.

Q J Nucl Med Mol Imaging. 2010 Aug;54(4):411-28. Review.

PMID:
20823809
15.

MIBG and somatostatin receptor analogs in children: current concepts on diagnostic and therapeutic use.

Pashankar FD, O'Dorisio MS, Menda Y.

J Nucl Med. 2005 Jan;46 Suppl 1:55S-61S. Review.

16.

Minimal residual disease in solid tumor malignancies: a review.

Ross AA.

J Hematother. 1998 Feb;7(1):9-18. Review.

PMID:
9507377
17.

Pharmacologic management of high-risk neuroblastoma in children.

Ganeshan VR, Schor NF.

Paediatr Drugs. 2011 Aug 1;13(4):245-55. doi: 10.2165/11591630-000000000-00000. Review.

Supplemental Content

Support Center